News for Healthier Living

Immunotherapy Improves Survival of Patients with Locally Advanced Head and Neck Cancer

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

April 27, 2025


May 9 2025

May 8 2025

May 7 2025

May 6 2025

May 5 2025

May 2 2025

May 1 2025

April 30 2025

April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025